Parkinson’s Disease Market Insights 2025-2034: Growth Dynamics, Trends, and Strategic Opportunities
Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What key factors are powering the surge in the parkinson’s disease market right now?
There has been a significant expansion in the market size for Parkinson’s disease in recent years. The market is expected to escalate from $3.34 billion in 2024 to $3.63 billion in 2025, reflecting a compound annual growth rate (CAGR) of 8.5%. The growth experienced in the historic period can be credited to factors such as the rise in research and development, increase in government funding, surge in personalized treatment regimes, expansion of support networks for those struggling with Parkinson’s disease and the growing application of sophisticated rehabilitation therapies.
How fast Is the parkinson’s disease market expected to grow, and what’s its future value?
Anticipations are high for a robust expansion in the market for Parkinson’s disease in the approaching years, with projections placing it at $4.98 billion by 2029, growing at a compound annual growth rate (CAGR) of 8.2%. Factors contributing to this projected growth within the forecast period include increased awareness about the symptoms of Parkinson’s disease, higher government involvement, increased spending on healthcare, an uptick in clinical trials for Parkinson’s disease, and a surge in the adoption of gene therapies. Forecasts for the period also highlight key trends like technological advancements, increased government initiatives and funding, the application of artificial intelligence in diagnostics, innovative solutions, and personalized medicine.
Get your parkinson’s disease market report here!
https://www.thebusinessresearchcompany.com/report/parkinsons-disease-global-market-report
What are the leading drivers of growth in the parkinson’s disease market?
The escalating occurrence of neurodegenerative diseases is predicted to fuel the expansion of the market for Parkinson’s disease. Neurodegenerative diseases consist of a series of disorders defined by the gradual degeneration and loss of neuron functionality within the brain and nervous system. The occurrence of these diseases is growing due to factors like an aging populace, genetic susceptibility, environmental factors, enhanced diagnosis, increasing chronic health conditions, and modifications in lifestyle. Parkinson’s disease contributes to the knowledge of neurodegenerative diseases by offering essential insights into their fundamental mechanisms, potential therapeutic targets, and the creation of groundbreaking treatment methods. For example, as stated by the European Brain Council in April 2022, a non-profit organization based in Belgium, over 600 neurological maladies and close to 300 psychiatric conditions affect millions worldwide, including 65 million suffering from epilepsy. In Europe, dementia affects 10.5 million individuals, with estimates predicting an increase to 18.7 million by 2050. Hence, the escalating occurrence of neurodegenerative diseases is boosting the expansion of the Parkinson’s disease market.
What are the key segments defining the parkinson’s disease market?
The parkinson’s disease market covered in this report is segmented –
1) By Drug Class: Dopamine Agonists, Catechol-O-Methyltransferase Inhibitors, Monoamine Oxidase B Inhibitors, Anticholinergics, Carbidopa-Levodopa, Other Drug Classes
2) By Route Of Administration: Oral, Injectable, Intestinal infusion, Subcutaneous, Other Route Of Administrations
3) By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, Online Pharmacies
4) By Patient Care Setting: Clinics, Hospitals
Subsegments:
1) By Dopamine Agonists: Ergot Derivatives, Non-Ergot Derivatives
2) By Catechol-O-Methyltransferase (COMT) Inhibitors: Entacapone, Tolcapone, Opicapone
3) By Monoamine Oxidase B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide
4) By Anticholinergics: Trihexyphenidyl, Benztropine, Procyclidine
5) By Carbidopa-Levodopa: Immediate-Release Formulation, Extended-Release Formulation, Inhaled And Intestinal Gel Formulations
6) By Other Drug Classes: Amantadine And Derivatives, Adenosine A2A Receptor Antagonists, Glutamate Antagonists
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21247&type=smp
Who are the key players steering the development of the parkinson’s disease market?
Major companies operating in the parkinson’s disease market are Roche Holding AG, AbbVie Inc., Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, UCB S.A., Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Amneal Pharmaceuticals Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc., Sunovion Pharmaceuticals Inc., Intracellular Therapies Inc., Voyager Therapeutics Inc., Sage Therapeutics Inc., Adamas Pharmaceuticals Inc., Sun Pharma Advanced Research Company Ltd., Neuraly Inc., Mitsubishi Tanabe Pharma Corporation, Athira Pharma Inc., VistaGen Therapeutics Inc.
What key trends are currently impacting the parkinson’s disease market’s development?
Leading firms in the parkinson’s disease market are concentrating on fostering innovative approaches, such as levodopa-based treatments, to enhance motor function and offer sustained symptom control for patients with advanced Parkinson’s disease. This treatment uses levodopa, a drug that transforms into dopamine in the brain, to boost motor function and reduce Parkinson’s symptoms. For example, in October 2024, the US-based biopharmaceutical entity, AbbVie Inc., obtained the US Food and Drug Administration (FDA) certification for VYALEV, a combined treatment comprising levodopa and carbidopa, developed for treating Parkinson’s disease. The aim of its formulation is to augment the effectiveness of levodopa by preventing its degradation before it arrives in the brain, thus elevating dopamine levels. This drug is successful in controlling motor signs of Parkinson’s disease, such as tremors, stiffness, and bradykinesia, which consequently improves the patient’s capability to perform everyday tasks. It is acknowledged as a crucial medicinal answer for Parkinson’s patients suffering from motor fluctuations.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21247
Which regions are most influential in expanding the parkinson’s disease market?
North America was the largest region in the parkinson’s disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the parkinson’s disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Hereditary Angioedema Therapeutics Global Market Report 2025
Angiotensin Receptor Blockers Global Market Report 2025
Cell and Gene Therapy Global Market Report 2025
https://thebusinessresearchcompany.com/report/cell-and-genes-therapy-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
